In a boost to Merck (MRK), the U.S. solicitor general is urging the U.S. Supreme Court to review a case that has broad ramifications for lawsuits filed by consumers against drug makers over product warnings.
At issue are hundreds of lawsuits that were filed more than seven years ago by women who claim they suffered bone fractures after taking Fosamax, a Merck drug used to combat osteoporosis. Last year, a federal appeals court overturned a lower court and decided the lawsuits should proceed.
About the Author Reprints
